DE-CSC
16.6.2020 14:02:12 CEST | Business Wire | Press release
CSC , a world leader in business, legal, tax, and domain security, today released its 2020 Domain Security Report: Forbes Global 2000 Companies from their Digital Brand Services (DBS) division. The report highlights significant shortfalls in enterprise domain security practices, putting organizations’ internet-facing digital assets at risk to threats, including domain name and domain name system (DNS) hijacking, phishing, and other fraudulent activity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200616005062/en/
According to the report, 83% of Global 2000 organizations have not adopted basic domain security measures such as registry lock, which puts them at risk for domain name hijacking. The report indicates a wide industry disparity in domain security maturity with information technology and media and entertainment industries more likely to embrace available security controls, while industries such as materials and real estate trail behind.
“These security shortfalls are the direct result of not executing proper domain security techniques. Domain security cannot be an afterthought, and there needs to be a conscious effort to make this an intentional and critical part of every company’s overall cyber security posture, especially as criminals evolve their attack methods,” says Mark Calandra, executive vice president for CSC DBS. “As companies move to more online business models, it’s essential to use defense-in-depth practices to proactively manage, secure, and defend the foundational internet-facing components of your digital brand presence.”
Additional highlights from the report include:
- Four out of five Global 2000 companies are severely at risk and exposed to domain name and DNS hijacking due to a lack of registry locks. Unlocked domains are vulnerable to social engineering tactics, which can lead to unauthorized DNS changes and domain name hijacking.
- 53% of the Forbes Global 2000 use retail-grade domain registrars, putting them at greater risk for phishing, social engineering, and attacks while complicating compliance demands. The management of the overall domain name portfolio by a reputable corporate registrar versus a retail registrar will make the adoption of domain security standards much easier to implement and monitor.
- Only 20% of Global 2000 companies use enterprise-grade DNS hosting. Lack of DNS hosting redundancy and using non-enterprise-level DNS providers poses potential security threats like resiliency to distributed denial of service (DDoS) attacks, as well as down time, and revenue loss.
- 97% of the Global 2000 don’t use DNS security extensions (DNSSEC), which means the majority of companies are prone to cache poisoning attacks. Lack of deployment of DNSSEC leads to vulnerabilities in the DNS, which could include an attacker hijacking any step of the DNS lookup process.
- Domain-based message authentication, reporting, and conformance (DMARC) use is only at 39% for the Global 2000 companies. DMARC is an email validation system designed to protect a company’s email domain from being used for email spoofing, phishing scams, and other cyber crime.
A core division of CSC, DBS is the trusted provider of choice for the Forbes Global 2000 and is the only enterprise-class registrar with a comprehensive set of solutions focused on defending businesses from targeted threat vectors to their domain names, DNS, and digital certificates. Moreover, the organization detects and mitigates online brand abuse, infringements, and fraud with the latest machine analysis and scoring technology to perform global enforcement, including takedowns and advanced techniques in internet blocking.
If you’re a member of SANS, to learn more, join CSC and SANS for a webinar Friday, June 19. Register here .
External links:
- Download the report here
- Domain Security Report blog post
- Infographic for Domain Security Report
About CSC
CSC is the trusted provider of choice for the Forbes Global 2000 and the 100 Best Global Brands® in enterprise domain names, domain name system (DNS), digital certificate management, as well as digital brand and fraud protection. As global companies make significant investments in their security posture, CSC can help them understand known security blind spots that exist and help them secure their digital assets. By leveraging CSC’s proprietary solutions, companies can get secure to protect against cyber threats to their online assets, helping them avoid devastating revenue loss, brand reputation damage, or significant financial penalties because of policies like the General Data Protection Regulation (GDPR). CSC also provides online brand protection—the combination of online brand monitoring and enforcement activities—taking a holistic approach to digital asset protection, along with fraud protection services to combat phishing. Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. Visit cscdbs.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005062/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
